1162 related articles for article (PubMed ID: 1928075)
21. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
[TBL] [Abstract][Full Text] [Related]
22. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
Ifudu O; Feldman J; Friedman EA
N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
[TBL] [Abstract][Full Text] [Related]
23. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization.
Servilla KS; Singh AK; Hunt WC; Harford AM; Miskulin D; Meyer KB; Bedrick EJ; Rohrscheib MR; Tzamaloukas AH; Johnson HK; Zager PG
Am J Kidney Dis; 2009 Sep; 54(3):498-510. PubMed ID: 19628315
[TBL] [Abstract][Full Text] [Related]
24. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency.
Raja R; Bloom E; Johnson R; Goldstein M
Adv Perit Dial; 1994; 10():135-8. PubMed ID: 7999811
[TBL] [Abstract][Full Text] [Related]
25. Erythropoietin and iron use in peritoneal dialysis patients. Report from the 1997 HCFA end-stage renal disease core indicators project.
Bailie GR; Frankenfield DL; Prowant BF; McClellan W; Rocco MV
Am J Kidney Dis; 1999 Jun; 33(6):1187-9. PubMed ID: 10352214
[TBL] [Abstract][Full Text] [Related]
26. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
[TBL] [Abstract][Full Text] [Related]
27. Erythropoietin associated hypertension among pediatric dialysis patients.
Komatsu Y; Ito K
Adv Perit Dial; 1992; 8():448-52. PubMed ID: 1361845
[TBL] [Abstract][Full Text] [Related]
28. [The use of recombinant erythropoietin with patients on programmed hemodialysis].
Rozental' RL; Zezina LIu; Spudass AV
Ter Arkh; 1991; 63(12):110-3. PubMed ID: 1803587
[TBL] [Abstract][Full Text] [Related]
29. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.
Eschbach JW; Egrie JC; Downing MR; Browne JK; Adamson JW
N Engl J Med; 1987 Jan; 316(2):73-8. PubMed ID: 3537801
[TBL] [Abstract][Full Text] [Related]
30. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis.
Więcek A; Ahmed I; Scigalla P; Koytchev R
Adv Ther; 2010 Dec; 27(12):941-52. PubMed ID: 20972656
[TBL] [Abstract][Full Text] [Related]
31. [The correction of anemia with a high requirement for transfusion in patients on maintenance hemodialysis by conventional and reduced doses of recombinant human erythropoietin].
Sivak L; Scuteri RM; Cavalli NH; Gotlieb D; López Blanco OA
Medicina (B Aires); 1992; 52(6):516-22. PubMed ID: 1340900
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the therapeutic efficacy of epoetin beta and epoetin alfa in maintenance phase hemodialysis patients.
Loughnan A; Ali GR; Abeygunasekara SC
Ren Fail; 2011; 33(3):373-5. PubMed ID: 21401367
[TBL] [Abstract][Full Text] [Related]
33. Subcutaneous recombinant human erythropoietin in patients on CAPD.
Lye WC; Lee EJ
Adv Perit Dial; 1991; 7():285-7. PubMed ID: 1680447
[TBL] [Abstract][Full Text] [Related]
34. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
Thanakitcharu P; Siriwiwatanakul N
J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
[TBL] [Abstract][Full Text] [Related]
35. Effect of darbepoetin alfa on renal anemia in Japanese hemodialysis patients.
Kusaba T; Ishida R; Nakayama M; Kato H; Uchiyama H; Sato K; Mori Y; Matsubara H; Kajita Y
Arzneimittelforschung; 2009; 59(9):435-9. PubMed ID: 19856789
[TBL] [Abstract][Full Text] [Related]
36. Erythropoietin for anaemia in haemodialysis patients: results of a maintenance study (the Canadian Erythropoietin Study Group).
Muirhead N; Laupacis A; Wong C
Nephrol Dial Transplant; 1992; 7(8):811-6. PubMed ID: 1325613
[TBL] [Abstract][Full Text] [Related]
37. [Utility of recombinant human erythropoietin on the anemia of elderly hemodialysis patients].
Ueyama H; Nakahashi H; Sawanishi K; Kuze M; Ono T
Hinyokika Kiyo; 1992 Dec; 38(12):1429-35. PubMed ID: 1288237
[TBL] [Abstract][Full Text] [Related]
38. Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta.
Gertz B; Kes P; Essaian A; Bias P; Buchner A; Zellner D
Curr Med Res Opin; 2012 Jul; 28(7):1101-10. PubMed ID: 22533679
[TBL] [Abstract][Full Text] [Related]
39. Clinical administration of epoetin alfa recombinant.
Taylor BA; Weinstein SM
J Intraven Nurs; 1992; 15(2):78-82. PubMed ID: 1564606
[TBL] [Abstract][Full Text] [Related]
40. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial.
Beiraghdar F; Panahi Y; Einollahi B; Nemati E; Ghadiani MH; Sahebkar A; Maghsoudi N; Marzony ET
Clin Lab; 2012; 58(7-8):737-45. PubMed ID: 22997974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
